How Medicines Law & Policy
is Aiding the Covid-19 Response
SEE COVID RESOURCES
European Union Review of Pharmaceutical Incentives:
Suggestions for Change
A new briefing paper series from Medicines Law & Policy
READ MORE
EU Review of Pharmaceutical
Incentives: Suggestions for Change
Medicines Law & Policy creates tools countries and others looking to increase access to medicines can use to overcome patent barriers when needed.
OUR TOOLS
Medicines Law & Policy maintains a database
documenting use of TRIPS Flexibilities
to increase access to medicines worldwide.
ACCESS THE TRIPS FLEXIBILITIES DATABASE
Medicines Law & Policy releases analysis,
policy recommendations and tools to aid practitioners
working on universal access to medicines.
OUR RESOURCES

Latest Posts

We need a Global Vaccines Taskforce, not just a British or European one

Christopher Garrison -
The European Commission has been heavily criticised for its performance over Covid-19 vaccine supply to European Union Member States. Despite the urgency of the...

The European Commission says Covid-19 vaccines should be global public goods, but do their...

Medicines Law & Policy -
By Ellen 't Hoen & Pascale Boulet The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is...

The elephant in the room at the WHO Executive Board

Ellen 't Hoen -
The World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus spoke harshly about the lack of Covid-19 vaccines in developing countries at the opening of...

Wrapping up 2020 with some noteworthy medicines, law and policy events

Medicines Law & Policy -
Wrapping up the year 2020 can’t happen soon enough. This year, one way or the other, most people on the planet have been affected...

Decision on intellectual property waiver over Covid technology on hold till 2021; what are...

Kaitlin Mara -
Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer. The...

What is the ‘know-how gap’ problem and how might it impact scaling up production...

Christopher Garrison -
This entire article is also available as a PDF by clicking here. 1. Introduction. How relevant are concerns about intellectual property rights causing problems for...

Subscribe to Our Newsletter

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).

Posts by Subject

Access to Medicines ARIPO C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Data exclusivity Delinkage DNDi dolutegravir European Commission European Union evergreening Fair Pricing Gilead Hepatitis C HIV IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands orkambi Orphan Drugs Patents PrEP R&D remdesivir Sofosbuvir SPC Supplementary Protection Certificates The Netherlands transparency TRIPS Council TRIPS flexibilities Truvada vaccines WHO WIPO WTO
 This work is licensed under Creative Commons.